Better survival in impaired renal function patients with metastatic non-small cell lung cancer treated by cisplatin-pemetrexed
ConclusionThe better survival rate in G2 and its correlation with pemetrexed and cisplatin treatments suggest that, until other therapeutic choices become available, a cautious increase in dosage could be investigated as a way to improve poor prognoses.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Alimta | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer | Statistics | Study | Toxicology | Urology & Nephrology